目前我国糖尿病患者数已接近1个亿,中国已成为全球范围糖尿病增长最快的地区,是世界糖尿病第一大国。然而,我国糖尿病治疗的现状并不容乐观,由于传统降糖药的治疗存在低血糖事件、体重增加和胰岛β细胞功能进行性减退等因素,极大程度限制了血糖控制的达标率和延缓糖尿病相关并发症的进展。由此可见,传统降糖药物已难以满 At present, the number of diabetic patients in China is close to 1 billion. China has become the fastest growing area for diabetes in the world and is the world’s number one diabetes country. However, the status quo of diabetes treatment in our country is not optimistic. Due to the existence of hypoglycemic events, weight gain and the progressive decline of pancreatic β-cell function, the treatment of traditional hypoglycemic agents greatly limits the rate of glycemic control and delays the diabetes-related Complication progress. This shows that the traditional hypoglycemic drugs have been difficult to full